Role of CDK9 in the Replication Stress Response
Role of CDK9 in the Replication Stress Response
批准号:
8195284
负责人:
David Sung-wen Yu
金额:
$16.46万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-07-01 至 2015-06-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The candidate is a radiation oncologist with the career objective of becoming an independent, self- funded, and productive academic physician-scientist, dedicated to unlocking the secrets of cancer biology and bridging the gap between its elucidation and improvement in clinical care. His specific research interest is in discovering the basic biological processes that govern genome integrity. His training goals during the mentored K08 award period are to acquire the foundation of knowledge and practical research skills necessary to initiate an independent research program investigating the Replication Stress Response. He will acquire a foundation of knowledge in checkpoint signaling to complement his prior training in DNA replication and DNA repair and expand his technical background with training in genetic and biochemical methodologies to complement his prior training in molecular biology and cell biology under a 5-year mentored training program using the outstanding resources and nurturing environment of Vanderbilt University Medical Center. The Replication Stress Response (RSR) is a subset of the DNA Damage Response that recognizes challenges to DNA replication and mobilizes cellular activities that lead to cell cycle arrest, DNA repair, or apoptosis. Mutations in the RSR promote the survival and proliferation of genetically unstable cells eventually leading to cancer. Thus the RSR acts as a cancer barrier. The candidate has completed a novel loss of function genetic screen using RNA interference in human cells to identify 14 high-confidence RSR genes, including the novel RSR gene, cyclin-dependent kinase 9 (CDK9). His preliminary studies show that CDK9 interacts in a complex or complexes with ATR/ATR interacting protein (ATRIP) as well as with other RSR proteins and localizes to ATRIP-containing foci. Moreover, his preliminary data indicate that the kinase activity of CDK9 is essential for recovery from replication arrest. Based on these data, he hypothesizes that CDK9 maintains genome integrity by participating in an ATR-mediated replication stress response through phosphorylation of key substrates. To test his hypothesis, he proposes the following specific aims: (1) Determine the regulation and functional significance of the interaction of CDK9 with ATR. (2) Identify substrates of CDK9. (3) Determine how the activity of CDK9 is regulated. These aims will be completed by a combination of genetic and biochemical approaches to provide a mechanistic understanding of CDK9 function. Completion of these aims will provide new insights into the how the RSR maintains genome integrity and prevents cancer. Moreover, this research has significant clinical application for developing innovative ways for diagnosing and treating cancer.
PUBLIC HEALTH RELEVANCE: This proposal will be completed by a combination of genetic and biochemical approaches to provide a mechanistic understanding of CDK9 function in the RSR. Completion of these aims will provide new insights into how the RSR maintains genome integrity and prevents cancer. Moreover, this research has significant clinical application for developing innovative ways for diagnosing and treating cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
T32 Training Program in Cancer Biology
-
批准号:10714463
-
项目类别:
-
资助金额:$16.63万
-
财政年份:2023
-
负责人:David Sung-wen Yu
-
依托单位:
P3: Molecular Mechanisms Underlying Therapy Response to Radiation and Immune Checkpoint BlockadeýSUBAWARD
-
批准号:10704715
-
项目类别:
-
资助金额:$26.69万
-
财政年份:2022
-
负责人:David Sung-wen Yu
-
依托单位:
P3: Molecular Mechanisms Underlying Therapy Response to Radiation and Immune Checkpoint BlockadeýSUBAWARD
-
批准号:10526305
-
项目类别:
-
资助金额:$23.64万
-
财政年份:2022
-
负责人:David Sung-wen Yu
-
依托单位:
Mechanisms of SIRT2 Function in the DNA Damage Response
-
批准号:10433994
-
项目类别:
-
资助金额:$34.4万
-
财政年份:2013
-
负责人:David Sung-wen Yu
-
依托单位:
Mechanisms of SIRT2 Function in the Replication Stress Response
-
批准号:8766965
-
项目类别:
-
资助金额:$7.26万
-
财政年份:2013
-
负责人:David Sung-wen Yu
-
依托单位:
Mechanisms of SIRT2 Function in the Replication Stress Response
-
批准号:8701259
-
项目类别:
-
资助金额:$31.4万
-
财政年份:2013
-
负责人:David Sung-wen Yu
-
依托单位:
Mechanisms of SIRT2 Function in the Replication Stress Response
-
批准号:9110215
-
项目类别:
-
资助金额:$32.37万
-
财政年份:2013
-
负责人:David Sung-wen Yu
-
依托单位:
Mechanisms of SIRT2 Function in the Replication Stress Response
-
批准号:8841506
-
项目类别:
-
资助金额:$2.5万
-
财政年份:2013
-
负责人:David Sung-wen Yu
-
依托单位:
Mechanisms of SIRT2 Function in the DNA Damage Response
-
批准号:9978732
-
项目类别:
-
资助金额:$35.1万
-
财政年份:2013
-
负责人:David Sung-wen Yu
-
依托单位:
Mechanisms of SIRT2 Function in the Replication Stress Response
-
批准号:8562313
-
项目类别:
-
资助金额:$32.37万
-
财政年份:2013
-
负责人:David Sung-wen Yu
-
依托单位:
Mechanisms of SIRT2 Function in the Replication Stress Response
-
批准号:9090220
-
项目类别:
-
资助金额:$7.49万
-
财政年份:2013
-
负责人:David Sung-wen Yu
-
依托单位:
Mechanisms of SIRT2 Function in the DNA Damage Response
-
批准号:10653826
-
项目类别:
-
资助金额:$34.4万
-
财政年份:2013
-
负责人:David Sung-wen Yu
-
依托单位:
Mechanisms of SIRT2 Function in the DNA Damage Response
-
批准号:10208792
-
项目类别:
-
资助金额:$35.1万
-
财政年份:2013
-
负责人:David Sung-wen Yu
-
依托单位:
Role of CDK9 in the Replication Stress Response
-
批准号:8494591
-
项目类别:
-
资助金额:$16.46万
-
财政年份:2010
-
负责人:David Sung-wen Yu
-
依托单位:
Role of CDK9 in the Replication Stress Response
-
批准号:8326198
-
项目类别:
-
资助金额:$16.46万
-
财政年份:2010
-
负责人:David Sung-wen Yu
-
依托单位:
Role of CDK9 in the Replication Stress Response
-
批准号:7773695
-
项目类别:
-
资助金额:$0.71万
-
财政年份:2010
-
负责人:David Sung-wen Yu
-
依托单位:
Role of CDK9 in the Replication Stress Response
-
批准号:8088123
-
项目类别:
-
资助金额:$15.75万
-
财政年份:2010
-
负责人:David Sung-wen Yu
-
依托单位:
国内基金
海外基金
登录
查看更多内容
香紫苏醇靶向CDK9抑制小胶质细胞炎症改善AD病理的作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:赵霞
-
依托单位:
新型CDK9抑制剂21e对PARPi耐药型卵巢癌的增敏作用机制
-
批准号:82304549
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:于辰华
-
依托单位:
靶向CDK9的PROTAC分子L055抑制ER阳性乳腺癌的功能和机制研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:吴皎
-
依托单位:
靶向降解 CDK9 的 PROTAC 分子的构建及抗肾透明细胞癌研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2022
-
负责人:
-
依托单位:
靶向CDK9杀伤皮肤T细胞淋巴瘤的机制、效应及原创PROTAC分子的设计合成与转化
-
批准号:--
-
项目类别:面上项目
-
资助金额:55万元
-
批准年份:2021
-
负责人:卢莹
-
依托单位:
血管平滑肌细胞CDK9 通过调节NF-κB 介导动脉粥样硬化的机制研究
-
批准号:LY22H070004
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:罗武
-
依托单位:
以“瞬时抑制”为特征的高选择性和高活性CDK9抑制剂的发现、结构优化及生物活性研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:55万元
-
批准年份:2021
-
负责人:陆涛
-
依托单位:
基于靶向CDK9选择性定量降解策略的小分子合成及其抗肾透明细胞癌的分子机制研究
-
批准号:82102746
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:敖名涛
-
依托单位:
CircFUNDC1/CDK9/RNA pol II构成的RNA调控网络在髓核细胞退变中的作用和机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:55万元
-
批准年份:2021
-
负责人:胡子昂
-
依托单位:
CDK9异常细胞质定位并通过降低内质网应激水平促进乳腺癌干细胞干性的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2021
-
负责人:郑飞猛
-
依托单位: